98%
921
2 minutes
20
The human APOBEC3A (A3A) polynucleotide cytidine deaminase has been shown to have antiviral activity against HTLV-1 but not HIV-1, when expressed in the virus producer cell. In viral target cells, high levels of endogenous A3A activity have been associated with the restriction of HIV-1 during infection. Here we demonstrate that A3A derived from both target cells and producer cells can block the infection of Moloney-MLV (MLV) and related AKV-derived strains of MLV in a deaminase-dependent mode. Furthermore, glycosylated Gag (glycoGag) of MLV inhibits the encapsidation of human A3A, but target cell A3A was not affected by glycoGag and exerted deamination of viral DNA. Importantly, our results clearly indicate that poor glycoGag expression in MLV gag-pol packaging constructs as compared to abundant levels in full-length amphotropic MLV makes these viral vectors sensitive to A3A-mediated restriction. This raises the possibility of acquiring A3A-induced mutations in retroviral gene therapy applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.virol.2021.01.017 | DOI Listing |
F1000Res
September 2025
Institute of Food and Biotechnology, Can Tho University, Can Tho City, Vietnam.
Background: has been extensively studied for its bioactive components and medicinal properties. This study was carried out to evaluate the fermentation ability of 2.1 yeast to determine suitable fermentation conditions.
View Article and Find Full Text PDFMol Cell Biol
September 2025
Laboratory of Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Mammalian cell membranes contain ether lipids, which include an alkyl chain derived from a fatty alcohol that is produced by fatty acyl-CoA reductases (FARs). There are two mammalian FAR genes, and , and mutations in cause the peroxisomal fatty acyl-CoA reductase 1 disorder (PFCRD), which is accompanied by various symptoms, including neurological disorders. To date, the contributions of and to brain ether lipid production and the molecular mechanism of PFCRD have remained unknown.
View Article and Find Full Text PDFPhilos Trans A Math Phys Eng Sci
September 2025
D-BAUG, ETH Zurich, Zürich 8093, Switzerland.
Biofilms-microbial communities encased in a self-produced extracellular matrix-pose a significant challenge in clinical settings due to their association with chronic infections and antibiotic resistance. Their formation in the human body is governed by a complex interplay of biological and environmental factors, including the biochemical composition of bodily fluids, fluid dynamics, and cell-cell and cell-surface interactions. Improving therapeutic strategies requires a deeper understanding of how host-specific conditions shape biofilm development.
View Article and Find Full Text PDFGenetics
September 2025
Department of Biology, McGill University, 3649 Sir William Osler, Montreal, Quebec, Canada H3G 0B1.
The E2F family of transcription factors are key regulators of the cell cycle in all metazoans. While they are primarily known for their role in cell cycle progression, E2Fs also play broader roles in cellular physiology, including the maintenance of exocrine tissue homeostasis. However, the underlying mechanisms that render exocrine cells particularly sensitive to E2F deregulation remain poorly understood.
View Article and Find Full Text PDFMol Ther
September 2025
Department of Medicine, UMass Chan Medical School, Worcester, MA, USA; Department of Genetic and Cellular Medicine, UMass Chan Medical School, Worcester, MA, USA; Horae Gene Therapy Center, UMass Chan Medical School, Worcester, MA, USA; Li Weibo Institute for Rare Diseases Research, UMass Chan Medic
The interleukin (IL)-1 pathway is a key mediator of inflammation and innate immune responses. Its dysregulation contributes to rheumatoid arthritis (RA) and autoinflammatory diseases (AIDs). In this study, we develop a recombinant adeno-associated virus (rAAV)-based gene therapy to deliver an inflammation-inducible, secreted human IL-1 receptor antagonist (sIL-1Ra) as a complementary approach to existing IL-1 blockers.
View Article and Find Full Text PDF